Icahn School of Medicine at Mount Sinai
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Ulcerative colitis
FollowWhat is new in Ulcerative colitis research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- ABX464Phase 3 · NCT05177835 · NCT05535946
- AfimkibartPhase 3 · NCT06588855 · NCT07665723 · NCT07846683 · NCT07158242 · NCT06589986
- DuvakitugPhase 3 · NCT07185009 · NCT07184996
- encapsulated faecal microbiotaPhase 3 · NCT03843385
- encapsulated faecal microbiota filtratePhase 3 · NCT03843385
- EtrasimodPhase 3 · NCT05287126 · NCT07470879 · NCT03950232
- Fecal microbiota transplantation (FMT)Phase 3 · NCT07154784 · NCT07814456 · NCT03483246
- FilgotinibPhase 3 · NCT06865417
- GolimumabPhase 3 · NCT05242484 · NCT03596645
- GuselkumabPhase 3 · NCT07577856 · NCT05242484 · NCT06663332 · NCT04033445
- Guselkumab Dose 1Phase 3 · NCT05528510
- Guselkumab Dose 2Phase 3 · NCT05528510
- Guselkumab Dose 3Phase 3 · NCT05528510
- Guselkumab IntravenousPhase 3 · NCT06260163
- Guselkumab SubcutaneousPhase 3 · NCT06260163
- Hemay005 tabletPhase 3 · NCT07650942
- IcotrokinraPhase 3 · NCT07196748
- InfliximabPhase 3 · NCT06453317 · NCT06614387 · NCT07297069 · NCT03596645
- IV PlaceboPhase 3 · NCT06052059
- IV TulisokibartPhase 3 · NCT06052059
- JNJ-78934804Phase 3 · NCT07577856 · NCT05242484
- MirikizumabPhase 3 · NCT07186101 · NCT03519945 · NCT04844606 · NCT06937086 · NCT06598943
- PonesimodPhase 3 · NCT07686081
- RisankizumabPhase 3 · NCT06880744 · NCT07071519 · NCT07697456 · NCT03398135 · NCT07177118
- SC PlaceboPhase 3 · NCT06052059
- SC TulisokibartPhase 3 · NCT06052059
- TirzepatidePhase 3 · NCT06937086
- TofacitinibPhase 3 · NCT07297069 · NCT04624230
- TulisokibartPhase 3 · NCT06651281
- UpadacitinibPhase 3 · NCT05782907
- Upadacitinib (ABT-494)Phase 3 · NCT03006068
- Upadacitinib Oral ProductPhase 3 · NCT06660693
- UstekinumabPhase 3 · NCT06453317 · NCT03167437 · NCT05092269 · NCT07177118
- VedolizumabPhase 3 · NCT06880744 · NCT04738942 · NCT06850727
- Vedolizumab IVPhase 3 · NCT03221036 · NCT06100289 · NCT05442567
- Vedolizumab SCPhase 3 · NCT06100289 · NCT06405087
- 0 g/d CICR-NAM (blinded)Phase 2/3 · NCT06488625
- 5-Aminosalicylic acid(5-ASA) and/or PrednisonePhase 2/3 · NCT03804931
- Fecal microbiota transplantationPhase 2/3 · NCT03804931
- High-Dose CICR-NAMPhase 2/3 · NCT06488625
- Infusion of SalinePhase 2/3 · NCT03804931
- Low-Dose CICR-NAMPhase 2/3 · NCT06488625
- ModafinilPhase 2/3 · NCT07582458 · NCT07295834
- Nitazoxanide (NTZ)Phase 2/3 · NCT07820046
- Open-LabelPhase 2/3 · NCT06488625
- OzanimodPhase 2/3 · NCT05076175
- 627Phase 2 · NCT07507513
- ABBV-701Phase 2 · NCT07697456
- AC-101Phase 2 · NCT07755241
- AdalimumabPhase 2 · NCT06257875
- Adalimumab-800CWPhase 2 · NCT03938701
- ALTB-268Phase 2 · NCT06109441
- anti-TL1A monoclonal antibody, high dosePhase 2 · NCT07080034
- anti-TL1A monoclonal antibody, low dosePhase 2 · NCT07080034
- anti-TL1A monoclonal antibody, medium dosePhase 2 · NCT07080034
- AquaminPhase 2 · NCT07501078
- Aquamin®Phase 2 · NCT03869905
- ATH-063Phase 2 · NCT07513181
- Atorvastatin CalciumPhase 2 · NCT04767984
- AzathioprinePhase 2 · NCT06213857
- Baitouweng TangPhase 2 · NCT06421818
- BI 3032950 intravenous (Part A)Phase 2 · NCT06636656
- BI 3032950 subcutaneous (Part B)Phase 2 · NCT06636656
- Biopsy of ColonPhase 2 · NCT04767984
- Biospecimen CollectionPhase 2 · NCT04767984 · NCT03816345
- BRS201Phase 2 · NCT06420375 · NCT06420492
- ButyratePhase 2 · NCT05218850
- D-2570Phase 2 · NCT07035041
- DesloratadinePhase 2 · NCT07333716
- DupilumabPhase 2 · NCT05731128
- EltrekibartPhase 2 · NCT06598943
- emvistegrastPhase 2 · NCT06290934
- Faecal microbiota transplantationPhase 2 · NCT04924270
- Fecal Microbiota Transplantation by Intra-rectal enemasPhase 2 · NCT05202990
- Fecal Microbiota Transplantation by Stool capsulesPhase 2 · NCT05202990
- Fluorescence ImagingPhase 2 · NCT03938701
- Hemay005 placebo tabletsPhase 2 · NCT05486104
- Hemay005 tabletsPhase 2 · NCT05486104
- High-dose MH002Phase 2 · NCT07296315
- HRS-7085Phase 2 · NCT07229950
- HSK47388Phase 2 · NCT07335055
- Identical Tacrolimus-free Lipid Suspension for EnemaPhase 2 · NCT06867042
- IPG11406Phase 2 · NCT07535489
- ISM5411 tabletsPhase 2 · NCT07265570
- Live SK08 powderPhase 2 · NCT06725017
- Low-dose MH002Phase 2 · NCT07296315
- LutikizumabPhase 2 · NCT06257875
- LY4268989Phase 2 · NCT07186101 · NCT07415044
- LY4268989 PlaceboPhase 2 · NCT07186101
- LY4395089Phase 2 · NCT07483073
- Lyophilized fecal microbiota (LFMT)Phase 2 · NCT05327790
- MesalaminePhase 2 · NCT06525974 · NCT07064707 · NCT06993974 · NCT07333716 · NCT05119140 · NCT07349472 · NCT06213857
- MetforminPhase 2 · NCT05574387
- Mirikizumab - Intravenous (IV)Phase 2 · NCT07483073
- Mirikizumab - Subcutaneous (SC)Phase 2 · NCT07483073
- MK-8690Phase 2 · NCT07463183
- MT-201Phase 2 · NCT07113522
- MT-501Phase 2 · NCT07113522
- NitazoxanidePhase 2 · NCT06993974
- nivolumabPhase 2 · NCT07223424 · NCT03816345
- OD-07656Phase 2 · NCT06850727
- Oral VancomycinPhase 2 · NCT07646223
- PALI-2108Phase 2 · NCT07428096 · NCT07845487
- pembrolizumabPhase 2 · NCT07223424
- PentoxifyllinePhase 2 · NCT07349472
- Phentermine-TopiramatePhase 2 · NCT04721873
- PL8177Phase 2 · NCT05466890
- PL8177 PlaceboPhase 2 · NCT05466890
- PRIM-DJ2727Phase 2 · NCT04373473
- PTT-621 TabletsPhase 2 · NCT07747155
- RO7837195Phase 2 · NCT06979336
- RO7837195 Matched PlaceboPhase 2 · NCT06979336
- RosnilimabPhase 2 · NCT06127043
- RupatadinePhase 2 · NCT07064707
- SAR442970Phase 2 · NCT06975722
- SAR443122Phase 2 · NCT05588843
- Selenium supplementationPhase 2 · NCT07427017
- SHR-1139 intravenous injection.Phase 2 · NCT07232576
- SPY001Phase 2 · NCT07012395 · NCT07652294
- SPY002Phase 2 · NCT07012395 · NCT07652294
- SPY003Phase 2 · NCT07012395 · NCT07652294
- Tacrolimus Lipid Suspension for enemaPhase 2 · NCT06867042
- TAK-279Phase 2 · NCT06254950
- TEV-48574 Dose Regimen APhase 2 · NCT05668013
- TEV-48574 Dose Regiment BPhase 2 · NCT05668013
- Tilpisertib FosmecarbilPhase 2 · NCT06029972
- Tofacitinib 10 MG [Xeljanz]Phase 2 · NCT04925973
- TRA16Phase 2 · NCT07871669
- TrosunilimabPhase 2 · NCT07697456
- Vancomycin (blinded)Phase 2 · NCT07341282
- Vancomycin (open-label extension)Phase 2 · NCT07341282
- Vancomycin /Amphotericin B (Fungizone®) /Gentamicine 80 mgPhase 2 · NCT07300553
- ZasocitinibPhase 2 · NCT06764615
- 25mg adalimumab-680LT and 15/25 mg risankizumab-800CWPhase 1/2 · NCT07258641
- Adalimumab-680LT 25mgPhase 1/2 · NCT07258641
- Amoxicillin hydrate/ Fosfomycin calcium hydrate/ MetronidazolePhase 1/2 · NCT07913347
- FMTPhase 1/2 · NCT05739864
- HydroxychloroquinePhase 1/2 · NCT05119140
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR TPhase 1/2 · NCT07544160
- INT-210 CapsulePhase 1/2 · NCT07692165
- Matching placebo to MB-001Phase 1/2 · NCT07374471
- MB-001Phase 1/2 · NCT07374471
- MGT-006Phase 1/2 · NCT07913347
- Risankizumab-800CW 15 mgPhase 1/2 · NCT06606808
- Risankizumab-800CW 15 mg/25 mgPhase 1/2 · NCT07258641
- Risankizumab-800CW 25 mgPhase 1/2 · NCT06606808
- Risankizumab-800CW 4.5 mgPhase 1/2 · NCT06606808
- Risankizumab-800CW optimal dosePhase 1/2 · NCT06606808
- sequential FMTPhase 1/2 · NCT06071312
- single FMTPhase 1/2 · NCT06071312
- Vancomycin hydrochloridePhase 1/2 · NCT07913347
- VorinostatPhase 1/2 · NCT03167437
- XmAb942Phase 1/2 · NCT06619990
- 24mg bid TQH3906 capsulePhase 1 · NCT06754891
- 32mg TQH3906 capsulePhase 1 · NCT06754891
- Adipose derived, autologous mesenchymal stem cellsPhase 1 · NCT04312113
- AletekitugPhase 1 · NCT07747480
- Aletekitug (GSK1070806)Phase 1 · NCT07747467
- Alpha-0261Phase 1 · NCT07744646
- ATTO-1091Phase 1 · NCT07819799
- BCD-261, dose 1Phase 1 · NCT06715540
- BCD-261, dose 2Phase 1 · NCT06715540
- BCD-261, dose 3Phase 1 · NCT06715540
- BCD-261, dose 4Phase 1 · NCT06715540
- BCD-261, dose 5Phase 1 · NCT06715540
- BCD-261, dose 6Phase 1 · NCT06715540
- BCD-261, pre-specified therapeautic dose XPhase 1 · NCT06715540
- BCD-261, pre-specified therapeautic dose YPhase 1 · NCT06715540
- BDHK-2009 TabletsPhase 1 · NCT07632573
- Biological: HX15001Phase 1 · NCT07768254
- CabozantinibPhase 1 · NCT03816345
- CaffeinePhase 1 · NCT07665723
- CKD-704Phase 1 · NCT07258745
- CM551Phase 1 · NCT07900945
- CP-101Phase 1 · NCT05852574
- CP-101 + PlaceboPhase 1 · NCT05852574
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cellsPhase 1 · NCT05003947
- DextromethorphanPhase 1 · NCT07665723
- EQ504Phase 1 · NCT07869225
- EQ504 PlaceboPhase 1 · NCT07869225
- Fecal Microbiota TransplantPhase 1 · NCT02636517
- FluoropyrimidinePhase 1 · NCT03816345
- GSK4528287Phase 1 · NCT06681181
- HRS-7085 tabletsPhase 1 · NCT07760831
- injection of CNK-UT009Phase 1 · NCT07416383
- IpilimumabPhase 1 · NCT03816345
- LIV001Phase 1 · NCT06749795
- LMT503Phase 1 · NCT05659953
- LYNC-101Phase 1 · NCT07505030
- LYNC-101 PlaceboPhase 1 · NCT07505030
- Matching placeboPhase 1 · NCT07834515
- MidazolamPhase 1 · NCT07665723
- OmeprazolePhase 1 · NCT07665723
- ONO-6414Phase 1 · NCT07749768
- Platinum CompoundPhase 1 · NCT03816345
- Platinum DoubletPhase 1 · NCT03816345
- PRIM-DJ2727 - CAPSULESPhase 1 · NCT05786404
- PRIM-DJ2727 - FROZENPhase 1 · NCT05786404
- R-3750Phase 1 · NCT05666960
- SHR-7590Phase 1 · NCT07758101
- SKYRIZIPhase 1 · NCT07258745
- TL-003Phase 1 · NCT07526519
- TP317Phase 1 · NCT07834515
- TQH3906 placeboPhase 1 · NCT06754891
- WarfarinPhase 1 · NCT07665723
- XylitolPhase 1 · NCT05852587
- BCMA CAR-T or CD19 CAR-T or CD19×BCMAEarly phase 1 · NCT07435779
- cizutamigEarly phase 1 · NCT07353450
- conventional treatmentEarly phase 1 · NCT05610956
- EmpagliflozinEarly phase 1 · NCT05610956
- exosomes derived from human umbilical cord mesenchymal stem cellsEarly phase 1 · NCT06853522
- FebuxostatEarly phase 1 · NCT06525974
- mesalazineEarly phase 1 · NCT07767370
- MTB-targeted phage therapyEarly phase 1 · NCT07878026
- ND-12Early phase 1 · NCT07767370
- ND-12/H-6Early phase 1 · NCT07767370
- Non-invasive vagus nerve stimulation (nVNS)Early phase 1 · NCT07636304
- RD06-05 CART Cell InfusionEarly phase 1 · NCT07309744
- saline +5% albuminEarly phase 1 · NCT06853522
Closest to patients
- Long-term Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Ulcerative ColitisLong-term Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Ulcerative ColitisSeoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine · Seoul, South KoreaPhase 2/3Primary completion 2023
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisA Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisMorehouse School of Medicine · Atlanta, United States + 347 more hospitalsPhase 2/3Primary completion 2023
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisA Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisIrmandade Santa Casa de Misericordia de Porto Alegre · Porto Alegre, Brazil + 46 more hospitalsPhase 3Primary completion 2023
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Corrigendum to "Curcumin-loaded Pickering emulsions stabilized by Spanish mackerel protein-pectin for ameliorating ulcerative colitis through barrier repair and anti-inflammatory effects" [Int. J. Biol. Macromol. 307 (2025) 141934].
Corrigendum to "Curcumin-loaded Pickering emulsions stabilized by Spanish mackerel protein-pectin for ameliorating ulcerative colitis through barrier repair and anti-inflammatory effects" [Int. J. Biol. Macromol. 307 (2025) 141934].
International journal of biological macromolecules
PubMed · PMID 42977662Publication
Identification of characteristic markers in Castanopsis fissa honey and its anti-inflammatory mechanism in ulcerative colitis: a multi-strategy approach.
Identification of characteristic markers in Castanopsis fissa honey and its anti-inflammatory mechanism in ulcerative colitis: a multi-strategy approach.
Journal of the science of food and agriculture
PubMed · PMID 42958924Publication
Zein-coated pH and inflammation-responsive sinapic acid-loaded 6-O-stearoyl-L-ascorbic acid and geraniol-based nanoparticles for treatment of acute DSS-induced ulcerative colitis.
Zein-coated pH and inflammation-responsive sinapic acid-loaded 6-O-stearoyl-L-ascorbic acid and geraniol-based nanoparticles for treatment of acute DSS-induced ulcerative colitis.
Journal of materials chemistry. B
PubMed · PMID 42949035Publication
Bletilla striata polysaccharide‑zinc complex ameliorates ulcerative colitis by modulating endoplasmic reticulum stress-associated autophagy and apoptosis.
Bletilla striata polysaccharide‑zinc complex ameliorates ulcerative colitis by modulating endoplasmic reticulum stress-associated autophagy and apoptosis.
Nanomedicine : nanotechnology, biology, and medicine
PubMed · PMID 42950938Publication
Engineering a self-assembled copper-quercetin nanocomposite via metal-natural product coordination for synergistic and enhanced therapy of ulcerative colitis.
Engineering a self-assembled copper-quercetin nanocomposite via metal-natural product coordination for synergistic and enhanced therapy of ulcerative colitis.
Colloids and surfaces. B, Biointerfaces
PubMed · PMID 42962586Publication
Ginseng-derived extracellular vesicles alleviate ulcerative colitis by regulating macrophage glycolytic reprogramming and H3K18la-mediated epigenetic modification.
Ginseng-derived extracellular vesicles alleviate ulcerative colitis by regulating macrophage glycolytic reprogramming and H3K18la-mediated epigenetic modification.
Journal of ginseng research
PubMed · PMID 42948586
Find fellow researchers
Groups with active Ulcerative colitis work.
IRCCS Ospedale San Raffaele
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Vita-Salute San Raffaele University
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
Universitair Ziekenhuis Leuven
Leuven, Belgium
Team details appear once the team leader joins.
Is this your team? Claim it
Western University
London, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Zhejiang University
Hangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
University of Calgary
Calgary, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
University of Chicago
Chicago, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Amsterdam University Medical Centers
Amsterdam, Netherlands
Team details appear once the team leader joins.
Is this your team? Claim it
Nanjing University of Chinese Medicine
Nanjing, China
Team details appear once the team leader joins.
Is this your team? Claim it